Neurofibromatosis is a suspected disease in the field of autoimmunity and rheumatoid immunity. Clinical performance is complex and often involves multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis.
The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. Treatment and management of neurofibromatosis is a multi-dimensional treatment program that includes individualized development, usually drug therapy, rehabilitation interventions, regular follow-up, and so on.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely schemes according to changes in conditions. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of neurofibromatosis.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.